Carmela Gonzales, MD
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $68,569 of the $98,019 with a category attached, or 70.0%. 32 manufacturers reported payments, led by Biogen at 55.7% of the total. Reporting peaked in 2019 at $41,852 and has fallen 97.0% since, to $1,246 in 2025. Among neurology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 387 payments — averaging $253.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$55K
- EMD Serono, Inc.$27K
- AbbVie$11K
- Novartis$4K
- Amgen$355
- Teva Pharmaceuticals USA, Inc.$193
- plus $1K from 26 others
What the payments were for
- Consulting fees$15,01115%
- Speaking & faculty fees$68,56970%
- Travel & lodging$5,1785%
- Food & beverage$9,1869%
- Education$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 100 | $54,594 |
| EMD Serono, Inc. | 111 | $27,127 |
| AbbVie(2 entities) | 54 | $10,848 |
| Novartis | 36 | $3,776 |
| Amgen | 10 | $355 |
| Teva Pharmaceuticals USA, Inc. | 13 | $193 |
| Sanofi | 7 | $138 |
| Lundbeck LLC | 3 | $128 |
| Lilly USA, LLC | 7 | $112 |
| AstraZeneca | 5 | $83 |
| CSL Behring | 4 | $76 |
| Argenx US, Inc. | 3 | $68 |
| Genentech USA, Inc. | 4 | $64 |
| Jazz Pharmaceuticals Inc. | 4 | $63 |
| Supernus Pharmaceuticals, Inc. | 3 | $51 |
| Eisai Inc. | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Harmony Biosciences LLC | 1 | $28 |
| Acadia Pharmaceuticals Inc | 2 | $27 |
| Sunovion Pharmaceuticals Inc. | 4 | $26 |
| UCB, Inc. | 1 | $22 |
| Adamas Pharmaceuticals, Inc. | 1 | $20 |
| Upsher-smith Laboratories LLC | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Bausch Health US, LLC | 1 | $18 |
| Tanabe Pharma America, Inc. | 1 | $17 |
| Neurelis, Inc. | 1 | $17 |
| Acorda Therapeutics, Inc | 1 | $14 |
| Pfizer | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| SK Life Science, Inc. | 1 | $12 |
| Genentech, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$98,019 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality SyringeGalcanezumab-Gnlm | 16 | $28,627 |
| Aimovig AutoinjectorErenumab-Aooe | 30 | $20,472 |
| MyrbetriqMirabegron | 16 | $17,115 |
| QuliptaAtogepant | 13 | $16,533 |
| Emgality PenGalcanezumab-Gnlm | 21 | $16,020 |
| Sumatriptan Succinate | 67 | $4,337 |
| Levetiracetam | 121 | $2,933 |
| Carbamazepine ErCarbamazepine | 24 | $2,579 |
| Dalfampridine ErDalfampridine | 31 | $2,505 |
| Divalproex Sodium | 39 | $1,736 |
| Gabapentin | 99 | $1,686 |
| Amitriptyline Hcl | 81 | $1,632 |
| Divalproex Sodium ErDivalproex Sodium | 41 | $1,624 |
| Tetrabenazine | 12 | $1,520 |
| Propranolol Hcl ErPropranolol Hcl | 34 | $1,508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta | $10,848 | $16,53313 claims |
| Upsher-smith Laboratories LLCTopiramate | $19 | $52545 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.
Other neurology in Miami
- Diego Torres-RussottoMiami$652K
- Bruno GalloMiami$313K
- Brad HerskowitzMiami$273K
- Flavia NelsonMiami$264K
- Corneliu LucaMiami$257K
- Kottil RammohanMiami$176K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.